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Abstract. Intact monoclonal antibodies with a high molecular weight tend to 
have a poor pharmacokinetic profile and tumor penetration, and potential for 
eliciting host antibody responses. F(ab’)2 fragments smaller than intact 
monoclonal antibodies that still maintain antigen binding could solve this 
problem. The objective of this study was to optimize the digestion process of 
nimotuzumab, an anti-EGFR monoclonal antibody, into its F(ab’)2 fragment and investigate its potential as a therapeutic radioimmunoconjugate. Optimal 
conditions for digestion of nimotuzumab to its F(ab’)2 fragment were found to be 6 hours of digestion time with a pH of 3.5 and 1:100 mol ratio of pepsin to 
nimotuzumab. The purity of the F(ab’)2-nimotuzumab was confirmed by SDS-PAGE and HPLC analysis. Prior to its labeling with lutetium-177 radionuclide, 
the nimotuzumab-F(ab’)2 was conjugated to DOTA-PAMAM dendrimer [DOTA denotes 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, PAMAM 
denotes poly(amidoamine)] to form conjugate of (DOTA)n-PAMAM-[nimotuzumab-F(ab’)2]. Radiolabeling of DOTA-PAMAM-[nimotuzumab-F(ab’)2] conjugate with 177Lu resulted in (177Lu-DOTA)n-PAMAM-[nimotuzumab-F(ab’)2] with radiochemical purity > 99% after purification with a PD-10 column. Further studies still need to be performed in order to confirm the 
potential of this radioimmunoconjugate as a radioimmunotherapeutic agent for 
EGFR overexpressed cancers. 
Keywords: dendrimer PAMAM; EGFR; nimotuzumab-F(ab’)2; pepsin digestion; 177Lu-
DOTA-PAMAM-[nimotuzumab-F(ab’)2]. 
1 Introduction 
Since 1981, several reports have been published concerning overexpression of 
the epidermal growth factor receptor (EGFR) on cancer cells [1-3]. One third of 
all epithelial cancers, such as head and neck cancer, colorectal carcinoma, non-
small cell lung cancer (NSCLC) and pancreatic cancer, have been reported to 
express a high level of EGFR. Overexpression of EGFR indicates tumor 
malignancy and poor prognosis of a cancer, and also correlates with cell 
Therapeutic Radioimmunoconjugate for EGFR O/C Treatment 259 
 
proliferation, metastases and radiation resistance [4,5]. Therefore, EGFR has 
been proposed as a target for cancer targeted therapy [2,6]. 
Nimotuzumab is a humanized monoclonal antibody that binds with domain III 
of the extracellular region of the EGFR [7]. Nimotuzumab has been used for the 
treatment of various carcinomas such a glioma, head and neck, lung, renal, 
colorectal, bladder, prostate, pancreatic, ovarian, cervical and breast cancer. 
Preclinical and clinical trials performed by Crombet, et al., showed that 
nimotuzumab has an antiproliferative, proapoptosis and antiangiogenic effect 
[6,8]. In a randomized open-label, phase-IIb, 5-year study on Indian patients, 
nimotuzumab was shown to provide a long-term survival benefit to patients 
with inoperable advanced squamous cell carcinoma of the head and neck [9]. 
Nimotuzumab has several advantages when compared with other anti EGFRs. 
These include having a more prolonged half-life in order to give optimum 
therapy and having no side effects such as skin rash, diarrhea or anaphylaxis, 
which are common in the use of other anti-EGFRs [3,6,4]. The use of 
nimotuzumab along with radiation therapy has been shown to enhance the 
effects of radiation therapy [7]. However, high molecular weight intact 
nimotuzumab has a poor pharmacokinetic profile [10].  
Monoclonal antibody (mAb) fragments are widely used to improve 
pharmacokinetic profiles [7,8]. MAb fragments have been reported to have 
better tumor penetration, more rapid blood clearance, lower retention time in 
non-target tissues and less immunogenicity. Uptake by mAb fragments is eight 
time faster than by intact monoclonal antibodies, so imaging can be performed 
on the same day as the administration of radioimmunoconjugate [11]. 
In recent days, polymeric biomaterials have become the central component of 
most new drug delivery systems. One of them is a family of water-soluble 
cascade polymers named poly(amidoamine) (PAMAM) dendrimers. PAMAM 
dendrimers have a high number of arms and surface amine groups so that they 
can be utilized to immobilize drugs, enzymes, antibodies or other bioactive 
agents. PAMAM dendrimers can also be used to improve the amount of 
therapeutic radionuclides delivered to cancer cells [12,13]. 
In this study, nimotuzumab-F(ab’)2 was used as one of the components of a 
building block for a new therapeutic radioimmunoconjugate. Lutetium-177 (Lu-
177) used as a therapeutic radionuclide with a bifunctional chelating agent of 
1,4,7,10-tetraazacyclododecane -1,4,7,10-tetraacetic acid mono-N-
hydroxysuccinimide ester (DOTA-NHS-ester). It should be noted that if a high 
number of DOTA directly binds to nimotuzumab-F(ab’)2, it could reduce the 
ability of the nimotuzumab-F(ab’)2 to bind to its receptor. Therefore, in this 
research PAMAM dendrimer was used for binding a large number of DOTA to 
260 Titis Sekar Humani, et al. 
produce (DOTA)n-PAMAM, followed by its conjugation onto nimotuzumab-
F(ab’)2. This technique is expected to offer a large amount of DOTA indirectly 
bound to nimotuzumab-F(ab’)2, which simultaneously binds the Lu-177 without 
compromising its immunoreactivity. 
2 Methods 
2.1 Chemicals 
Nimotuzumab/TheraCIM was purchased from Kalbe Farma Tbk. Pepsin from 
porcine gastric mucosa was purchased from Sigma and used without further 
purification. Monobasic sodium phosphate, dibasic sodium phosphate and N,N-
dimethylformamide were purchased from Sigma. Laemli sample buffer, 10x 
tris/glycine/SDS buffer, Coomasie brilliant blue G-250, Chelex 100 resin, 
protein standard and protein dye were purchased from Bio-Rad. Acetic acid 
glacial 100% anhydrous, natrium acetate trihydrate, methanol, natrium 
hydroxide, hydrochloric acid 32%, sodium chloride, ammonium acetate and 
ethylene diamine tetraacetic acid were acquired from Merck.  Enriched lutetium 
oxide (60.60%) was purchased from Isoflex. Dendrimer PAMAM G.3 was 
purchased from Sigma-Aldrich. DOTA-NHS-ester was purchased from 
Macrocyclics. Traut’s reagent (2-Iminothiolane HCl), sulfo-SMCC [sulfo-
succinimidyl-4-(N-maleimidomethyl) cyclohexane 1-carboxylate] and dialysis 
cassettes (20kDa MWCO) were purchased from Thermo Scientific. A PD-10 
column was purchased from GE Healthcare. Instant thin-layer chromatography 
(ITLC SG) was purchased from Gelman Science. 
2.2 Instruments 
Equipment used for the experiment: thermomixer (Eppendorf), centrifuge 
(Beckman), mini protean tetra system (Bio-Rad), water purification system 
(Sartorius Stedim Biotech), high-performance liquid chromatography (Waters) 
equipped with a size exclusion column (BioSuite) and UV-visible detector 
(Waters), microplate reader (Biotek Instruments), gamma counter (Nucleus) and 
dose calibrator (Capintec). 
2.3 Preparation and Characterization of Nimotuzumab F(ab’)2 
Fragments 
Nimotuzumab was fragmented using pepsin with a similar method as reported 
by Hao Hong, et al., [11]. Termination of the fragmentation process, unlike 
reported by R.D. Haryuni, et al., [14], where Tris HCL 10 mM pH 8 was used, 
in this project was performed by adjusting the pH of the solution to 8 using 0.1 
N NaOH. Samples were analyzed by sodium dodecyl sulfate-polyacrylamide 
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gel electrophoresis (SDS-PAGE) under non-reducing procedure to identify the 
optimal digestion condition. Purification of the nimotuzumab-F(ab’)2 fragments 
was carried out using the PD-10 column with phosphate buffered saline (PBS) 
as the mobile phase. The eluted molecules were detected using Biorad-dye, 
giving a blue color. The purity of the nimotuzumab-F(ab’)2 fragments was 
evaluated using size exclusion column chromathography with  0.01 N 
phosphate buffered saline (PBS) pH 7,4 as the mobile phase. Finally, the 
concentration of the nimotuzumab-F(ab’)2 fragments was determined by 
microplate reader using UV-absorbance at 280 nm.   
2.4 Conjugation of DOTA PAMAM Nimotuzumab-F(ab’)2 
Fragments 
Dendrimer PAMAM was added to the sulfo-NHS-DOTA, which had been 
previously dissolved in 0.1 M phosphate buffer pH 7.2 (mol ratio dendrimer 
PAMAM to sulfo-NHS-DOTA was 1:96). The pH was then adjusted to 7.2. 
After 24 hours incubating at 4 °C, the mixture was purified using the PD-10 
column with 0.05 M phosphate buffer pH 7.4 as mobile phase. Fractions 
containing DOTA-PAMAM were collected, followed by addition of 2-
iminothiolane-HCl solution (in 0.05 M phosphate buffer pH 7.4, 1 mg/mL) at 
proportional mol ratio. The mixture was incubated for an hour (in nitrogen gas 
flow) and then purified using the PD-10 column. The thiolated DOTA-PAMAM 
fractions were mixed with the maleimide-activated nimotuzumab-F(ab’)2 
fragments [15]. The maleimide-activated Nimotuzumab-F(ab’)2 fragments were 
prepared by adding sulfo-SMCC (sulfo-SMCC was dissolved in DMF and then 
diluted with 0.1 M phosphate buffer pH 7.2 to get a concentration of 1 mg/mL) 
to the nimotuzumab-F(ab’)2 fragments, with the mol ratio of sulfo-SMCC to 
nimotuzumab-F(ab’)2 fragments at 10-fold molar excess. The mixture was 
incubated for 30 minutes at room temperature and then purified using the PD-10 
column. The mixture of thiolated DOTA-PAMAM and the maleimide-activated 
nimotuzumab-F(ab’)2 fragments (mol ratio 10:1) was incubated for 24 hours at 
4 °C followed by dialysis against 0.25 ammonium acetate pH 7.5 and Chelex 
100 with 4 buffer changes every 12 hours.  
2.5 Labeling of (DOTA)n-PAMAM-[Nimotuzumab-F(ab’)2 
Fragments] 
177LuCl3 was prepared by iradiating 176Lu2O3 (60.60% enriched) in a Multi 
Purpose Research Reactor (BATAN, Indonesia) for 4 days. The irradiated target 
was then moved to a beaker glass and added with 2 mL of H2O2. The mixture 
was heated until dried and then redissolved in 3 mL of HCl 0.5 N. 
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The 177LuCl3 (19 mCi) was diluted with 0.25 M ammonium acetate pH 7.5 (1:1 
v/v) and then added to (DOTA)n-PAMAM-[nimotuzumab-F(ab’)2 fragments]. 
The pH of the mixture solution was adjusted to 5.5, followed by incubating for 
1 hour at 37 °C. Purification of the radioimmunoconjugate, (177Lu-DOTA)n-
PAMAM-[nimotuzumab-F(ab’)2], was performed using the PD-10 column with 
0.01 N phosphate buffer saline pH 7.4 as the mobile phase. 
3 Results and Discussion 
In a previous study, radioimmunoconjugate 177Lu-DOTA-nimotuzumab with 
high radiochemical purity was successfully prepared [16]. However, intact 
monoclonal antibodies tend to have a relatively poor pharmacokinetic profile 
and tumor penetration, and potential for eliciting host antibody responses [17]. 
Therefore, in this study we prepared an antibody fragment-based 
radioimmunoconjugate (177Lu-DOTA)n-PAMAM-[nimotuzumab-F(ab’)2] to 
achieve faster tumor penetration and blood clearance. F(ab’)2 fragments were 
prepared by digestion of whole or intact nimotuzumab using pepsin.  The choice 
for F(ab’)2 fragments was due to their bivalent form. These fragments still have 
two antibody arms that are able to bind to two targets simultaneously, which is 
important for maintaining prolonged drug residence in tumors and is an 
important feature for inhibiting tumor growth [18]. Optimization of digestion 
time at 37 °C (pH 3.5) and a pepsin to nimotuzumab mol ratio of 1:50 for 
generating nimotuzumab-F(ab’)2 without the presence of intact nimotuzumab 
was achieved at 6 hours of digestion time (Figure 1). SDS-PAGE gel (Figure 1) 
showed that there were two bands of interest in determining the results of 
nimotuzumab digestion. The band at 150 kDa indicates intact nimotuzumab 
while the 100 kDa band shows nimotuzumab-F(ab’)2. 
 
Figure 1 SDS-PAGE of protein standard, intact nimotuzumab, pepsin, and 
nimotuzumab fragments. Arrows indicate the absent of intact nimotuzumab (150 
kD MW) at 6 hours digestion time. 
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The effect of the pepsin to nimotuzumab mol ratio was investigated by varying 
it at 1:200, 1:100, 1:50, 1:20, 1:10, 1:5 and 1:1. The nimotuzumab was found 
completely digested to its F(ab’)2 fragments by using pepsin to nimotuzumab 
with a mol ratio of 1:100 and up to 1:1 (data not shown). When the mol ratio of 
pepsin to nimotuzumab was 1:20 and up to 1:1 the mixture became turbid, 
which is allegedly caused by nimotuzumab damage. At this mol ratio, the 
concentration of pepsin to antibody species is significantly high; the enzyme not 
only digests the antibody into dimeric F(ab’)2 and Fc fragments, but it may also 
attack the antigen binding site on the Fab. Pepsin is usually used to fragment 
and cleave proteins on many points to give small peptides (3-30 residues). The 
active conformation of pepsin appears at an optimal pH of around 2, while at 
pH above 7, pepsin is in denatured conformation. This denaturation is not fully 
reversible [19].  
Optimization of digestion time and the amount of pepsin are crucial because the 
affinity of nimotuzumab-F(ab’)2 can be diminished or eliminated if the 
incubation is too long or the concentration of pepsin is too high. The digestion 
process has been reported to be highly variable, which results in many different 
protocols for individual antibody species and amounts digested [20]. In further 
digestion, performed with an incubating time of 6 hours and a pepsin to 
nimotuzumab mol ratio of 1:100. Termination of the fragmentation process was 
carried out by adjusting the pH to 8. The generated nimotuzumab-F(ab’)2 was 
then purified from byproducts such as nimotuzumab-Fc, nimotuzumab-Fab, 
pepsin, etc. using the PD-10 column. The purity of nimotuzumab-F(ab’)2 was 
evaluated using a size exclusion column chromatographic system. Figure 2 
shows the chromatograms of nimotuzumab-F(ab’)2 before and after purification. 
 
Figure 2 Chromatograms of nimotuzumab-F(ab’)2, before (a) and after (b) purification. 
 (a) 
 
 (b) 
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It can be seen that before purification there were some peaks that depict the 
F(ab’)2, Fab, Fc and several small fragments of nimotuzumab (Figure 2a). After 
purification however, the obtained –nimotuzumab F(ab’)2 was found as a single 
peak, which indicates high purity (Figure 2b).  
The maleimide-activated nimotuzumab-F(ab’)2 was then conjugated to 
(DOTA)n-PAMAM dendrimer, which had been activated previously with 
Traut’s reagent to form (DOTA)n-PAMAM-[nimotuzumab-F(ab’)2]. The main 
purpose of using PAMAM dendrimer is to increase the number of DOTA 
indirectly bound to nimotuzumab-F(ab’)2, which in turn would maximize the 
number of 177Lu bounds in the building blocks of (177Lu-DOTA)n-PAMAM-
[nimotuzumab-F(ab’)2] (Figure 3). As a large amount of 177Lu-DOTA does not 
directly bind to nimotuzumab-F(ab’)2, which functions as a delivery agent of the 
(177Lu-DOTA)n-PAMAM-[nimotuzumab-F(ab’)2] to the EGF receptor, the 
immunoreactivity of nimotuzumab-F(ab’)2 would be expected to be relatively 
intact.  
 
Figure 3 Building block of (177Lu-DOTA)n-PAMAM-[nimotuzumab-F(ab’)2]. The figure is created using ChemDraw Ultra 8.0. 
Figure 4 shows radiochromatograms of (DOTA)n-PAMAM-[nimotuzumab-
F(ab’)2] triplicate labeling with 177Lu. It can be seen that the radiochemical 
purity of the (177Lu-DOTA)n-PAMAM-[nimotuzumab-F(ab’)2] resulted from the 
radiolabeling processes was 69.59±1.66%. In order to obtain a 
radioimmunoconjugate that has radiochemical purity > 95% (requirement for a 
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good radiopharmaceutical), the (177Lu-DOTA)n-PAMAM-[nimotuzumab-
F(ab’)2] was purified using the PD-10 column. Fractions (250 mL/ fraction) 
were then retrieved. Each fraction was then measured for its radioactivity by 
using a dose calibrator. A radiochromatogram of the purified (177Lu-DOTA)n-
PAMAM-[nimotuzumab-F(ab’)2] is shown in Figure 5.  
 
Figure 4 Labeling efficiency of (DOTA)n-PAMAM-[nimotuzumab-F(ab’)2] with 177Lu radionuclide. 
 
Figure 5 Radiochromatogram of purified (177Lu-DOTA)n-PAMAM-[nimotuzumab-F(ab’)2]. 
It can be seen that there are two peaks in the radiochromatogram of the purified 
(177Lu-DOTA)n-PAMAM-[nimotuzumab-F(ab’)2]. These peaks represent 
(177Lu-DOTA)n-PAMAM-[nimotuzumab-F(ab’)2] (fraction 11 – 17) and free 177Lu (177Lu which does not bind to (DOTA)n-PAMAM-[nimotuzumab-
F(ab’)2]). The radiochemical purity of fractions under the (177Lu-DOTA)n-
PAMAM-[nimotuzumab-F(ab’)2] peak was then analysed using thin-layer 
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chromatography, where ITLC-SG was used as stationary phase and saline 
solution as mobile phase. The radiochemical purity of fraction 12-15 was found 
to be 99.61±0.27% (Figure 6). These fractions were pooled and used for further 
studies. 
 
Figure 6 Radiochemical purity of 177Lu-DOTA-PAMAM-[nimotuzumab-
F(ab’)2]. 
4 Conclusion 
Optimal conditions for digestion of nimotuzumab into F(ab’)2 fragments using 
pepsin were achieved. Nimotuzumab was completely digested at a pepsin to 
nimotuzumab mol ratio of 1:100, a pH of 3.5, and 6 hours digestion time. 
Preparation of radioimmunoconjugate (177Lu-DOTA)n-PAMAM-
[nimotuzumab-F(ab’)2] was successfully conducted, with a labeling yield of 
69.59±1.66% and radiochemical purity of > 99% after purification with a PD-10 
column. For further research it is advised to perform a biodistribution test of 
radioimmunoconjugate (177Lu-DOTA)n-PAMAM-[nimotuzumab-F(ab’)2] and 
then compare its pharmacokinetic profile with that of radioimmunoconjugate 
(177Lu-DOTA)n-PAMAM-nimotuzumab.  
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